 - REZUROCK is approved for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy - - Kadmon to Host Conference Call on Monday, July 19, 2021 at 8:00 a.m. ET - NEW YORK, NY ACCESSWIRE July 16, 2021 Kadmon Holdings, Inc. Nasdaq:KDMN today announced that the U.S. Food and Drug Administration FDA has approved REZUROCK TM belumosudil 200 mg once daily QD for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease cGVHD after failure of at least two prior lines of systemic therapy. 